Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness

Inclusion Criteria: Patients eligible for inclusion in this Treatment Plan have to meet all of the following criteria: Written patient informed consent or assent must be obtained prior to start of treatment. * Patients aged ≥ 6 years * Patients clinically diagnosed with SARS-CoV-2 infection, either through positive serum antibodies (IgM or IgG); or by PCR; or by other approved diagnostic methodology. Patients with presumptive diagnosis of COVID-19 (other respiratory causes ruled out and SARS-CoV-2 test pending) may be included. * Adult and adolescent patients (≥12years), who meet one of the below criteria * Respiratory frequency ≥ 30/min * Oxygen saturation ≤ 93% on room air (FiO2=0.21) * Arterial oxygen partial pressure (PaO2)/ fraction of inspired oxygen (FiO2) \<300mmHg(1mmHg=0.133kPa) (corrective formulation should be used for higher altitude regions (over 1000m). AND \-- Patients with lung imaging showing pulmonary infiltrates (chest X-ray or CT scan) Pediatric patients (≥6-\<12 years) who meet one of the below criteria (where appropriate): * Shortness of breath * Oxygen saturation \<92% on room air (Fi)2=0.21) * Labored breathing (e.g. wheezing, flaring of nostrils, three concave sign), cyanosis, intermittent apnea. * Lethargy or convulsions * Refusal to eat or difficulty with feeding; signs of dehydration Exclusion Criteria: * Patients eligible for this Treatment Plan must not meet any of the following criteria: * History of hypersensitivity to any drugs or metabolites of similar chemical classes as ruxolitinib * Presence of severely impaired renal function defined by serum creatinine \> 2 mg/dL (\>176.8 μmol/L), or have estimated creatinine clearance \< 30 ml/min measured or calculated by Cockroft Gault equation or calculated by the updated bedside Schwartz equation. * Pregnant or nursing (lactating) women. * Patients who are NOT able to understand and to comply with treatment instructions and requirements unless health care proxy is able to provide consent.